Immunohistochemistry Ki67 Test: Comprehensive Cancer Cell Proliferation Analysis
Understanding the Immunohistochemistry Ki67 Test
The Immunohistochemistry Ki67 Test represents a cutting-edge diagnostic approach in modern oncology that evaluates the proliferation activity of cancer cells. This sophisticated laboratory technique detects the presence and distribution of the Ki67 protein, a nuclear antigen exclusively expressed in actively dividing cells during all phases of the cell cycle except the resting phase (G0). The test provides clinicians with quantitative data about tumor growth dynamics, making it an indispensable tool for cancer diagnosis, prognosis assessment, and treatment planning.
Scientific Foundation and Clinical Significance
Ki67, named after the city of Kiel where it was discovered and the clone number 67, serves as a reliable biomarker for cellular proliferation. The protein’s expression correlates directly with the tumor’s growth fraction – the percentage of cells actively undergoing division. Higher Ki67 indices typically indicate more aggressive tumor behavior, faster growth rates, and potentially poorer clinical outcomes. This molecular insight enables healthcare providers to stratify patients into appropriate risk categories and tailor therapeutic interventions accordingly.
What the Ki67 Test Measures and Detects
The Immunohistochemistry Ki67 Test specifically identifies and quantifies:
- Cell Proliferation Rate: Measures the percentage of tumor cells actively dividing
- Ki67 Protein Expression: Detects nuclear localization of Ki67 antigen in cancer cells
- Tumor Growth Fraction: Calculates the proportion of proliferating versus non-proliferating cells
- Cancer Aggressiveness: Provides indirect assessment of tumor malignancy potential
- Treatment Response Prediction: Helps forecast how tumors might respond to specific therapies
Who Should Consider the Ki67 Test
This diagnostic test is particularly valuable for patients with:
- Newly Diagnosed Cancers: Especially breast cancer, lymphoma, neuroendocrine tumors, and brain tumors
- Suspected Aggressive Tumors: When rapid growth or high-grade malignancy is suspected
- Treatment Planning Needs: To determine appropriate chemotherapy or radiation therapy protocols
- Prognostic Assessment: For establishing baseline tumor characteristics and predicting outcomes
- Therapy Monitoring: To evaluate treatment effectiveness during follow-up biopsies
- Recurrent Cancer Cases: When assessing changes in tumor behavior over time
Key Benefits of Ki67 Testing
Undergoing Immunohistochemistry Ki67 testing offers multiple clinical advantages:
- Personalized Treatment Planning: Enables customized therapy based on individual tumor characteristics
- Accurate Prognostic Information: Provides reliable data for predicting disease progression and survival rates
- Therapeutic Decision Support: Guides selection of appropriate chemotherapy regimens and treatment intensity
- Monitoring Treatment Response: Allows assessment of therapy effectiveness through sequential testing
- Risk Stratification: Helps categorize patients into low, intermediate, or high-risk groups
- Clinical Trial Eligibility: Often required for participation in advanced cancer research studies
Understanding Your Ki67 Test Results
Interpreting Ki67 results requires professional medical expertise, but general guidelines include:
- Low Ki67 Index (0-15%): Typically indicates slow-growing tumors with better prognosis
- Intermediate Ki67 (16-30%): Suggests moderate proliferation activity requiring careful monitoring
- High Ki67 (>30%): Often associated with aggressive tumors needing intensive treatment
- Context Matters: Results must be interpreted considering tumor type, location, and other clinical factors
- Follow-up Required: Always discuss results with your oncologist for personalized interpretation
Test Pricing and Availability
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $88 |
| Regular Price | $138 |
Turnaround Time and Sample Requirements
Our laboratory maintains efficient processing with the following timelines:
- Sample Collection: Daily by 6 PM
- Report Generation: Block samples: 5 days | Tissue Biopsy: 5 days | Complex Tissue: 7 days
- Sample Type: Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block
- Shipping: Room temperature transport
- Required Documentation: Histopathology report, biopsy site details, and clinical history
Nationwide Accessibility
GGC DNA maintains comprehensive testing facilities across the United States, with specialized branches in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network ensures convenient access to advanced diagnostic services regardless of your location.
Take Control of Your Cancer Care Today
Understanding your tumor’s proliferation characteristics through Ki67 testing can significantly impact your treatment journey and outcomes. Our experienced team of oncologists and pathologists are ready to provide you with accurate, reliable results and comprehensive interpretation.
Ready to schedule your Immunohistochemistry Ki67 Test? Contact our dedicated patient care team today to book your appointment or discuss your testing needs.
Call or WhatsApp: +1(267) 388-9828
Take the first step toward personalized cancer management with precise diagnostic insights from GGC DNA – your trusted partner in advanced oncology diagnostics.
